Efficacy
PD, tumor, SD
DISEASE, PROGRESSION, TUMOR, DISEASE
Of 30 patients, 2 could not be evaluated because they did not complete the computed tomography examination after undergoing one treatment cycle. Among 28 patients with evaluable efficacy, PR was obtained in 15, SD in 8, and PD in 5. The ORR was 53.6% (95% CI, 33.9–72.5%), and the DCR was 82.1% (95% CI, 63.1–93.9%) (Table 
Summary of tumor response and survival data*CR: Complete responsePR: Partial responseSD: Stable diseasePD: Progressive diseaseNE: Not evaluableORR: Objective response rateDCR: Disease control rateDOR: Duration of responsePFS: Progression Free SurvivalOS: Overall SurvivalCI: Confidence interval
Waterfall plot of the best percentage change from baseline in measurable tumor lesions of 28 measurable patients (A) and duration of response (According to the best percentage change from baseline in measurable tumor lesions, responder was defined as the patient who had a complete response (CR) or partial response (PR), while non-responder was defined as the patient who had a stable disease (SD) or progressive disease (PD).
Kaplan-Meier survival curves of progression-free survival (PFS) (A) and overall survival (OS) (B) in full analysis set of the 30 patients